Skip to content

Replimune Group REPL Free cash flow

Free cash flow at other companies

Amgen logo
AmgenAMGN
$1.48B+50.7%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$848.3M+4.0%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$38.03M-5.9%
Immunome logo
ImmunomeIMNM
-$61.64M-8.7%
CG Oncology logo
CG OncologyCGON
-$57.25M-95.4%
Erasca, Inc. logo
Erasca, Inc.ERAS
-$27.42M+13.3%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Calculated from Replimune Group’s reported figures.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's free cash flow?
Replimune Group (REPL) reported free cash flow of -$66.09M in Q4 2025.
How has Replimune Group's free cash flow changed year-over-year?
Replimune Group's free cash flow decreased by 25.9% year-over-year, from -$52.51M to -$66.09M.
What is the long-term trend for Replimune Group's free cash flow?
Over 3 years (2022 to 2025), Replimune Group's free cash flow has grown at a 33.0% compound annual growth rate (CAGR), from -$84.52M to -$198.94M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.